Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system

International Immunopharmacology

Volumn 1, Issue 6, 2001, Pages 1123-1130

  Hedlund, Gunnar ^a   Link, Hans ^b   Zhu, Jie ^b   Xiao, Bao Guo ^b  

^a Active Biotech Research AB   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cytokines; Linomide; Nervous system

Indexed keywords

COLLAGEN TYPE 2; CYCLOPHOSPHAMIDE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; ROQUINIMEX; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; GUILLAIN BARRE SYNDROME; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MOUSE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RAT; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM; CYTOKINES; HUMANS; HYDROXYQUINOLINES; IMMUNITY, CELLULAR; PERIPHERAL NERVOUS SYSTEM;

EID: 0035026188     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00041-8     Document Type: Review

References (65)

1. Kalland T., Alm G., Stålhandske T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J. Immunol. 134:1985;3956-3961.
2. Stålhandske T., Kalland T. Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the rat. Immunopharmacology. 11:1986;87-92.
3. Larsson E.L., Joki A., Stålhandske T. Mechanism of action of the new immunomodulator LS2616 on T cell responses. Int. J. Immunopharmacol. 9:1987;425-431.
4. Wanders A., Larsson E., Gerdin B., Tufveson G. Abolition of the effect of cyclosporine on rat cardiac allograft rejection by the new immunomodulator LS-2616 (Linomide). Transplantation. 47:1989;216-217.
5. Kalland T. Regulation of natural killer progenitors: studies with a novel immunomodulator with distinct effects at the precursor level. J. Immunol. 144:1990;4472-4476.
6. Gonzalo J.A., González-García A., Kalland T., Hedlund G., Martínez A.C., Kroemer G. Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur. J. Immunol. 23:1993;2372-2374.
7. Gonzalo J.A., González-García A., Kalland T., Hedlund G., Martínez A.C., Kroemer G. Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur. J. Immunol. 24:1994;48-52.
8. Johnsson C., Tufveson G. The immunomodulator LS-2616 (Linomide) more effectively than sensitization of the donor enhances graft-versus-host reaction after small bowel transplantation. Transplant Immunol. 2:1994;56-60.
9. Harring A.C., Xu Z., Andersson G., Hedlund G. Linomide enhances apoptosis in CD4+CD8+thymocytes. Scand. J. Immunol. 46(5):1997;488-494.
10. Kalland T. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res. 46:1986;3018-3022.
11. Ilbäck N.G., Fohlman J., Friman G. The anti-inflammatory effect of LS 2616 and poly I:C in coxsackievirus B3 induced murine myocarditis. Antiviral Res. 10:1988;129-140.
12. Ilbäck N.G., Fohlman J., Slorach S., Friman G. Effects of the immunomodulator LS 2616 on lymphocyte subpopulations inmurine coxsackievirus B3 myocarditis. J. Immunol. 142:1989;3225-3228.
13. Vukanovic J., Passaniti A., Hirata T., Traystman R.J., Hartley-Asp B., Isaacs J.T. Antiangiogenic effects of the quinoline-3-carboxamide Linomide. Cancer Res. 53:1993;1833-1837.
14. Borgström P., Torres Filho I.P., Vajkoczy P., Strandgården K., Polacek J., Hartley-Asp B. The quinoline-3-carboxamide, Linomide inhibits angiogenesis in vivo. Cancer Chemother. Pharmacol. 34:1994;280-286.
15. Hartley-Asp B., Vukanovic J., Joseph I.B., Strandgarden K., Polacek J., Isaacs J.T. Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. J. Urol. 158(3 Pt 1):1997;902-907.
16. Joseph I.B., Isaacs J.T. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J. Natl. Cancer Inst. 90(21):1998;1648-1653.
17. Del Real G., Llorente M., Bosca L., Hortelano S., Serrano A.et al. Suppression of HIV-1 infection in linomide-treated SCID-hu-PBL mice. AIDS. 12(8):1998;865-872.
18. Tarkowski A., Gunnarsson K., Nilsson L.Å., Lindholm L., Stålhandske T. Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immuno-modulator. Arthritis Rheum. 29:1986;1405-1409.
19. Spetz-Hagberg A.L., Larsson-Sciard E.L. Decreased levels of pathogenic IgG anti-DNA antibodies in autoimmune mice after Linomide treatment. Res. Immunol. 140:1989;517-525.
20. Carlsten H., Tarkowski A., Nilsson L.Å. The effect of immunomodulating treatment on cutaneous delayed-type hypersensitivity in MRL lpr/lpr mice. APMIS. 97:1989;728-732.
21. Spetz-Hagberg A.L., Goldschmidt T., Stålhandske T., Larsson-Sciard E.L. Amelioration of intrathymic T cell development and peripheral T cell reactivities in autoimmune mice under-going therapy with a novel immunomodulator. Int. Immunol. 2:1990;645-650.
22. 1 hybrid mice. Immunology. 59:1986;589-594.
23. Björk J., Kleinau S. Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice. Agents Actions. 27:1989;319-321.
24. Gross D.J., Sidi H., Weiss L., Kalland T., Rosenmann E., Slavin S. Prevention of diabetes in non-obese diabetic mice by Linomide, a novel immunomodulating drug. Diabetologia. 37:1994;1195-1201.
25. Shirkey B.L., Slavin S., Vistica B.P., Podgor M.J., Gery I. Immunomodulatory effects of linomide in animals immunized with immunopathogenic retinal antigens: dissociation between different immune functions. Clin. Exp. Immunol. 108(3):1997;539-544.
26. Hutchings P., Hedlund G., Dawe K., Howlett S., Cooke A. Efffect of the synthetic immunomodulator, linomide, on experimental models of thyroiditis. Immunology. 96(3):1999;340-347.
27. Zhang, X.W. , Liu, Q., Hedlund, G., Thorlacius, H., Linomide inhibits dextran sodium sulfate-induced murine colitits, submitted for publication.
28. Lindstrom J., Shelton D., Fujii Y. Myasthenia gravis. Adv. Immunol. 42:1988;233-285.
29. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330:1994;1797-1810.
30. Asthana D., Fujii Y., Huston G.E., Lindstrom J. Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis. Clin. Immunol. Immunopathol. 67:1993;240-248.
31. Karussis D.M., Lehmann D., Brenner T., Wirguin I., Mizrachi-Koll R.et al. Immuno-modulation of experimental autoimmune myasthenia gravis with Linomide. J. Neuroimmunol. 55:1994;187-193.
32. Zhang G.X., Yu L.Y., Shi F.D., Xiao B.G., Björk J.et al. Linomide suppresses both Th1 and Th2 cytokines in experimental autoimmune myasthenia gravis. J. Neuroimmunol. 73:1997;175-182.
33. Sidman C.L., Marshall J.D., Shultz L.D., Gray P.W., Johnson H.M. IFN-γ is one of several direct B cell-maturing lymphokines. Nature. 309:1984;801-804.
34. Skoskiewicz M.H., Callin R.B., Sternberger E.E., Russel P.S. Wide-spread and selective induction of major histocompatibility complex determined antigens in vivo by interferon. J. Exp. Med. 162:1985;1645-1664.
35. Adams D., Hamilton T.A. Molecular transductional mechanisms by which IFN-γ and other signals regulate macrophage development. Immunol. Rev. 97:1987;5-27.
36. Collart M.A., Belin J., Vassalli D., de Kossodo S., Vassalli P. IFN-γ enhances macrophage transcription of the TNF/cachetin, IL-1 and urokinase genes, which are controlled by short-lived repressors. J. Exp. Med. 164:1986;2113-2118.
37. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature. 314:1985;537-539.
38. Toyka K.V., Heininger K. Humoral factors in peripheral nerve disease. Muscle Nerve. 10:1987;222-232.
39. Raine C.S., Bornstein M. Experimental allergic neuritis-ultrastructure of serum induced myelin aberrations in peripheral nervous system cultures. Lab. Invest. 40:1979;423-432.
40. Saida T., Saida K., Silberberg D.H., Brown M.J. Transfer of demyelination by injection of experimental allergic neuritis serum. Nature. 272:1978;639-641.
41. Raine C.S. Experimental allergic encephalomyelitis and experimental allergic neuritis. Vinken P.J.et al. Handbook of clinical neurology. vol. 47:1985;429-466 Elsevier, Amsterdam.
42. Bai X.F., Shi F.D., Xiao B.G., Hedlund G., Link H. Linomide-induced suppression of experimental autoimmuine neuritis is associated with down-regulated macrophage functions. J. Neuroimmunol. 76:1997;177-184.
43. Zhu J., Bai X.F., Hedlund G., Björk J., Bakhiet M.et al. Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses. Clin. Exp. Immunol. 115:1999;56-63.
44. Karpati T., Karussis D., Abramsky O., Mizrahi-Koll R., Arbell I., Ovadia H. Inhibition of experimental autoimmune neuritis by the immunomodulator linomide. Immunol. Lett. 63(3):1998;141-145.
45. Strigård K., Holmdahl R., van der Meide P.H., Klareskog L., Olsson T. In vivo treatment of rats with monoclonal antibodies against gamma interferon: effects on experimental allergic neuritis. Acta Neurol. Scand. 80:1989;201-207.
46. Hartung H.P., Schäfer B., van der Meide P.H., Fierz W., Heininger K., Toyka K.V. The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system. Ann. Neurol. 27:1990;247-257.
47. Van der Meide P.H., de Labie M.C., Ruuls S.R., Groenestein R.J., Botman C.A.et al. Discontinuation of treatment with IFN-β leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-β and excessive expansion of autoreactive T cells as disease promoting. J. Neuroimmunol. 84:1998;14-23.
48. Yasuda C.L., Al-Sabbagh A., Oliveira E.C., Diaz-Bardales B.M., Garcia A.A., Santos L.M. Interferon beta modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion. Immunol. Invest. 28:1999;115-126.
49. Teitelbaum D., Fridkis-Hareli M., Arnon R., Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64:1996;209-217.
50. Teitelbaum D., Arnon R., Sela M. Copolymer 1: from basic research to clinical application. Cell. Mol. Life Sci. 53:1997;24-28.
51. Arnason B.G. Immunologic therapy of multiple sclerosis. Annu. Rev. Med. 50:1999;291-302.
52. Aharoni R., Teitelbaum D., Sela M., Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 94:1997;10821-10826.
53. Karussis D.M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R.et al. Inhibition of acute experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide. Ann. Neurol. 34:1993;654-660.
54. Karussis D.M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R.et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc. Natl. Acad. Sci. U. S. A. 90:1993;6400-6404.
55. Diab A., Levi M., Wahren B., Deng G.M., Bjork J.et al. Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines. J. Neuroimmunol. 85:1998;146-154.
56. Zhu J., Diab A., Mustafa M., Levi M., Wahren B.et al. Linomide suppresses chronic-relapsing experimental autoimmune encephalomyelitis in DA rats. J. Neurol. Sci. 160:1998;113-120.
57. Erälinna J.P., Roytta M., Hukkanen V., Zinhu D., Salmi A.A., Salonen R. Selective downregulation of Th1 response by Linomide reduces autoimmunity but increases susceptibility to viral infection in BALB/c and SJL mice. J. Neuroimmunol. 88(1-2):1998;165-176.
58. Andersen O., Lycke J., Tollesson P.O., Svenningsson A., Runmarker B.et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology. 47:1996;895-900.
59. Karussis D.M., Meiner Z., Lehmann D., Gomori J.M., Schwarz A.et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology. 47:1996;341-346.
60. Nosewothy J.H., Wolinsky J.S., Lublin F.D., Whitaker J.N., Linde A.et al. Linomide in relapsing and secondary progressive MS: Part I. Trial design and clinical results. Neurology. 54(9):2000;1726-1733.
61. Wolinsky J.S., Narayana P.A., Noseworthy J.H., Lublin F.D., Whitaker J.N., Linde A.et al. Linomide in relapsing and secondary progressive MS: Part II. MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology. 54(9):2000;1734-1741. May 9.
62. Tan I.L., Lycklama A., Nijeholt G.J., Polman C.H., Ader H.J., Barkhof F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult. Scler. 6(2):2000;99-104. April.
63. Dahlen E., Andersson M., Dawe K., Tellander A.C., Brunmark C., Bjork A.et al. Inhibition of autoimmune disease by the immunomodulator linomide correlates with the ability to activate macrophages. Autoimmunity. 32(3):2000;199-211.
64. Abramsky O., Lehmann D., Karussis D. Immunomodulation with linomide: possible novel therapy for multiple sclerosis. Mult. Scler. 2(4):1996;206-210.
65. Zhang X.W., Hedlund G., Borgström P., Arfors K.E., Thorlacius H. Linomide abolishes leukocyte adhesion and extravascular recruitment induced by tumor necrosis factor-α in vivo. J. Leukocyte Biol. 68(5):2000;621-626.